Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on August 12, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on August 12, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 40 Common Stock at $507.08 ($20,283) on August 12, 2026; holds 333,903 after (Indirect).
- Open-market sale: disposed of 440 Common Stock at $508.86 ($223,898) on August 12, 2026; holds 333,463 after (Indirect).
- Open-market sale: disposed of 280 Common Stock at $509.61 ($142,691) on August 12, 2026; holds 333,183 after (Indirect).
- Open-market sale: disposed of 1,152 Common Stock at $511.12 ($588,808) on August 12, 2026; holds 332,031 after (Indirect).
- Open-market sale: disposed of 542 Common Stock at $511.75 ($277,367) on August 12, 2026; holds 331,489 after (Indirect).
- Open-market sale: disposed of 1,206 Common Stock at $513.02 ($618,698) on August 12, 2026; holds 330,283 after (Indirect).
- Open-market sale: disposed of 558 Common Stock at $514.18 ($286,915) on August 12, 2026; holds 329,725 after (Indirect).
- Open-market sale: disposed of 893 Common Stock at $514.87 ($459,783) on August 12, 2026; holds 328,832 after (Indirect).
- Open-market sale: disposed of 940 Common Stock at $516.16 ($485,191) on August 12, 2026; holds 327,892 after (Indirect).
- Open-market sale: disposed of 1,249 Common Stock at $517.21 ($646,001) on August 12, 2026; holds 326,643 after (Indirect).
- Open-market sale: disposed of 320 Common Stock at $518.16 ($165,810) on August 12, 2026; holds 326,323 after (Indirect).
- Open-market sale: disposed of 1,160 Common Stock at $519.49 ($602,607) on August 12, 2026; holds 325,163 after (Indirect).
- Open-market sale: disposed of 679 Common Stock at $520.38 ($353,337) on August 12, 2026; holds 324,484 after (Indirect).
- Open-market sale: disposed of 41 Common Stock at $520.96 ($21,359) on August 12, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on August 12, 2026; holds 151,410 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $4,892,748 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Option exercise/conversion | Common Stock | 9,500 | $135 | $1.3M | 333,943 |
| 2026-08-12 | Open-market sale | Common Stock | 40 | $507 | $20.3K | 333,903 |
| 2026-08-12 | Open-market sale | Common Stock | 440 | $509 | $223.9K | 333,463 |
| 2026-08-12 | Open-market sale | Common Stock | 280 | $510 | $142.7K | 333,183 |
| 2026-08-12 | Open-market sale | Common Stock | 1,152 | $511 | $588.8K | 332,031 |
| 2026-08-12 | Open-market sale | Common Stock | 542 | $512 | $277.4K | 331,489 |
| 2026-08-12 | Open-market sale | Common Stock | 1,206 | $513 | $618.7K | 330,283 |
| 2026-08-12 | Open-market sale | Common Stock | 558 | $514 | $286.9K | 329,725 |
| 2026-08-12 | Open-market sale | Common Stock | 893 | $515 | $459.8K | 328,832 |
| 2026-08-12 | Open-market sale | Common Stock | 940 | $516 | $485.2K | 327,892 |
| 2026-08-12 | Open-market sale | Common Stock | 1,249 | $517 | $646.0K | 326,643 |
| 2026-08-12 | Open-market sale | Common Stock | 320 | $518 | $165.8K | 326,323 |
| 2026-08-12 | Open-market sale | Common Stock | 1,160 | $519 | $602.6K | 325,163 |
| 2026-08-12 | Open-market sale | Common Stock | 679 | $520 | $353.3K | 324,484 |
| 2026-08-12 | Open-market sale | Common Stock | 41 | $521 | $21.4K | 324,443 |
| 2026-08-12 | Option exercise/conversion | Stock Option | 9,500 | — | — | 151,410 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Option exercise/conversion (9,500 shares) |
| 2026-08-12 | Open-market sale (40 shares) |
| 2026-08-12 | Open-market sale (440 shares) |
| 2026-08-12 | Open-market sale (280 shares) |
| 2026-08-12 | Open-market sale (1,152 shares) |
| 2026-08-12 | Open-market sale (542 shares) |
| 2026-08-12 | Open-market sale (1,206 shares) |
| 2026-08-12 | Open-market sale (558 shares) |
| 2026-08-12 | Open-market sale (893 shares) |
| 2026-08-12 | Open-market sale (940 shares) |
| 2026-08-12 | Open-market sale (1,249 shares) |
| 2026-08-12 | Open-market sale (320 shares) |
| 2026-08-12 | Open-market sale (1,160 shares) |
| 2026-08-12 | Open-market sale (679 shares) |
| 2026-08-12 | Open-market sale (41 shares) |
| 2026-08-12 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.